Antisense and RNA interference approaches to target validation in pain research

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 2, 2004, Pages 179-187

  Kurreck, Jens ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Antisense oligonucleotides; Central nervous system; Pain; RNA interference; Small interfering RNA; Target validation

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DOUBLE STRANDED RNA; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY; PLASMID DNA; PLASMID VECTOR; PROTEIN KINASE R; RNA BINDING PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE;

ALLODYNIA; BLOOD BRAIN BARRIER; CANCER; CHRONIC PAIN; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RESEARCH; FUNCTIONAL GENOMICS; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GLIOBLASTOMA; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PAIN; REPORTER GENE; RETINITIS; REVIEW; RNA INTERFERENCE; VIRUS INFECTION; ANIMAL; DRUG DESIGN; DRUG EFFECT; GENE THERAPY; METHODOLOGY;

ANIMALS; DRUG DESIGN; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PAIN; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 12544254978     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Scholz J, Woolf CJ: Can we conquer pain? Nat Neurosci (2002) (Suppl 5):1062-1057.
2. Gillen C, Maul C: New pharmacological strategies for pain relief. Expert Rev Neurotherapeutics (2002) 2(5):691-702.
3. Opalinska JB, Gewirtz AM: Nucleic acids therapeutics: Basic principles and recent applications. Nat Rev Drug Disc (2002) 1(7):503-514.
4. Kurreck J: Antisense technologies: Improvement through novel chemical modifications. Eur J Biochem (2003) 270(8):1628-1644.
5. Sohail M, Southern EM: Selecting optimal antisense reagents. Adv Drug Deliv Rev (2000) 44(1):23-34.
6. Stein CA: The experimental use of antisense oligonucleotides: A guide for the perplexed. J Clin Invest (2001) 108(5):641-644.
7. Eckstein F: Phosphorothioate oligonucleotides: What is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev (2000) 10(2):117-121.
8. Levin AA: A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta(1999) 1489(1):69-84.
9. Peng Ho S, Livanov V, Zhang W, Li J, Lesher T: Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS. Mol Brain Res (1998) 62(1):1-11.
10. Hua X-Y, Moore A, Malkmus S, Murray SF, Dean N, Yaksh TL, Butler M: Inhibition of spinal protein kinase C□ expression by an antisense oligonucleotide attenuates morphine infusion-induced tolerance. Neuroscience (2002) 113(1):99-107.
11. Braasch DA, Corey DR: Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry (2002) 41(14):4503-4510.
12. Petersen M, Wengel J: LNA: A versatile tool for therapeutics and genomics. Trends Biotechnol (2003) 21(2):74-81.
13. Kurreck J, Wyszko E, Gillen C, Erdmann VA: Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res (2002)30(9):1911-1918.
14. Grünweiler A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J: Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res (2003) 31(12):3185-3193.
15. Porreca F, Lai J, Bian D, Wegert S, Ossipov MH, Eglen RM, Kassotakis L, Novakovic S, Rabert DK, Sangameswaran L, Hunter JC: A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Natl Acad Sci USA (1999) 96(14):7640-7644. This article describes the intrathecal application of AS ONs and validates the functional role of tetrodoxin-insensitive sodium channels.
16. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hökfelt T, Broberger C, Porreca F, Lai J, Ren K, Ossipov M et al: Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA (2000) 97(10):5633-5638. Antisense oligonucleotides containing locked nucleic acids can be used to knockdown gene expression in the brain in the absence of detectable toxic side effects.
17. Crooke ST: Progress In antisense technology: The end of the beginning. Methods Enzymol (2000) 313:3-45. A good overview of antisense applications in vitro and in vivo. It is the introductions to volumes 313 and 314 of Methods Enzymology, which contain a comprehensive collection of articles on various aspects of antisense technology.
18. v1.8. Pain (2002) 95(1-2):143-152.
19. 3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain (2002) 99(1-2):11-19.
20. Noda K, Anzai T, Ogata M, Akita H, Ogura T, Saji M: Antisense knockdown of spinal-mGluR1 reduces the sustained phase of formalin-induced nociceptive responses. Brain Res (2003) 987(2):194-200.
21. Stone LS, Vulchanova L: The pain of antisense: In vivo application of antisense oligonucleotides for functional genomics in pain and analgesia. Adv Drug Deliv Rev (2003) 55(8):1081-1112.
22. 3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and Inflammatory pain. J Neurosci (2002) 22(18):8139-8147.
23. v1.8-resistant sodium channel C-fibers causes retrograde mechanical nociceptor sensitization. Proc Natl Acad Sci USA (2003) 100(5):2923-2928.
24. v1.3 and functional involvement In neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J Neurosci (2003) 23(26):8881-8892.
25. Caterina MJ, Schumacher MA, Tominaga TA, Rosen TA, Levine JD, Julius D: The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature (1997) 389(6653):816-824. Describes the cloning and characterization of the capsaicin receptor, a major breakthrough in nociceptor biology that triggered numerous similar studies.
26. Garzon J, de Antonio I, Sanchez-Blázquez P: In vivo modulation of G proteins and opioid receptor function by antisense oligodeoxynucleotides. Methods Enzymol (2000) 314:3-20.
27. Przewlocka B, Sieja A, Starowicz K, Maj M, Bilecki W, Przewlocki R: Knockdown of spinal opioid receptors by antisense targeting β-arrestin reduces morphine tolerance and allodynia in rat. Neurosci Lett (2002) 325(2):107-110.
28. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic Interference by double-stranded RNA In Caenorhabditis elegans. Nature (1998) 391(6669):806-811. The first evidence that double-stranded RNA can mediate sequence-specific gene silencing is reported.
29. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference In cultured mammalian cells. Nature (2001) 411 (6836):494-498. One of the most important papers that has been published within the last few years, demonstrating that sequence-specific gene silencing by RNAi can be induced in mammalian cells by introduction of siRNAs.
30. Dykxhoorn D, Novina CD, Sharp PA: Killing the menssenger: Short RNAs that silence gene expression. Nat Rev Mol Cell Biol (2003) 4(6):457-467.
31. Scherr M, Morgan MA, Eder M: Gene silencing mediated by small interfering RNAs In mammalian cells. Curr Med Chem (2003) 10(3):245-256.
32. Sioud M: Therapeutic siRNAs. Trends Pharmacol Sci (2004) 25(1):22-28.
33. Miyagishi M, Hayashi M, Taira K: Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets In mammalian cells. Antisense Nucleic Acid Drug Dev (2003) 13(1):1-7.
34. Kretschmer-Kazemi Far R, Sczakiel G: The activity of siRNA in mammalian cells is related to structural target accessibility: A comparison with antisense oligonucleotides. Nucleic Acids Res (2003) 31 (15):4417-4424.
35. Shi Y: Mammalian RNAi for the masses. Trends Genet (2003) 19(1):9-12.
36. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short Interfering RNAs In mammalian cells. Science (2002) 296(5567):550-553.
37. Van De Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, Van Leenen D, Holstege FC, Brummelkamp TR, Agami R, Clevers H: Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep (2003) 4(6):609-615. Description of a system for inducible expression of shRNA. Regulation of RNAi is desirable for many applications and will facilitate the design of control experiments.
38. Czauderna F, Santel A, Hinz M, Fechtner M, Durieux B, Fisch G, Leenders F, Arnold W, Giese K, Klippel A, Kaufmann J: Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res (2003) 31 (21):e127. Demonstrates the applicability of an inducible shRNA expression vector in vivo.
39. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J: RNA Interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 9(3)347-351. One of the first applications in which RNAi is used to target a medically relevant gene in vivo. Treatment of mice with siRNA significantly improved the survival rate after induction of hepatitis.
40. Zender L, Hütker S, Liedtke C, Tillmann HL, Zender S, Mundt B, Waltemathe M, Gösling T, Flemming P, Malek NP, Trautwein C et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA (2003) 100(13):7797-7802.
41. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA: Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol (2003) 21(6):639-644. This study demonstrates that RNAi can inhibit viral replication in vivo.
42. Brummelkamp TR, Bernards R, Agami R: Stable suppression of tumorgenicity by virus-mediated RNA interference. Cancer Cell (2002) 2(3):243-247.
43. Abbas-Terki T, Blanco-Bose W, Déglon N, Pralong W, Aebischer P: Lentiviral-mediated RNA interference. Human Gene Ther (2002) 13(18):2197-2201.
44. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Ihrig MM, McManus MT, Gertler FB, Scott ML et al: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet (2003) 33(3):401-406.
45. Zhao LJ, Jian H, Zhu H: Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene (2003) 316(October 16):137-141.
46. Xia H, Mao Q, Paulson HL, Davidson BL: siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol (2002) 20(10):1006-1010.
47. Tomar RS, Matta H, Chaudhary PM: Use of adeno-associated viral vector for delivery of small Interfering RNA. Oncogene (2003) 22(36):5712-5715.
48. Hommel JD, Sears RM, Georgescu D, Simmons DI, DiLeone R: Local gene knockdown in the brain using viral-mediated RNA interference. Nat Med (2003) 9(12):1539-1544.
49. Kamath RS, Fraser AG, Dong Y, Poulin G, Durbin R, Gotta M, Kanapin A, Le Bot N, Moreno S, Sohrmann M, Welchman DP et al: Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature (2003) 421 (6920):231-237. Demonstrates that RNAi is suitable for a genome-wide analysis of loss-of-function phenotypes.
50. Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J, Ruvkun G: Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature (2003) 421 (6920):268-272.
51. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R: Loss of cylindromatosis tumor suppressor inhibits apoptosis by activating NF-κB. Nature (2003) 424(6950):797-801.
52. Prankish H: Consortium uses RNAi to uncover genes' function. Lancet (2003) 361(9357):584.
53. Krichevsky AM, Kosik KS: RNAI functions In cultured mammalian neurons. Proc Natl Acad Sci USA (2002)99(18):11926-11929. Convincing demonstration that RNA interference functions in mammalian neurons.
54. Gan L, Anton KE, Masterson BA, Vincent VA, Ye S, Gonzales-Zulueta M: Specific Interference with gene expression and gene function mediated by long dsRNA In neuronal cells. J Neurosci Methods (2002) 121(2):151-157.
55. Gaudillière B, Shi Y, Bonni A: RNA interference reveals a requirement for myocyte enhancer Factor 2A in activity-dependent neuronal survival. J Biol Chem (2002) 277(48):46442-46446.
56. Grünweller A, Gillen C, Erdmann VA, Kurreck J: Cellular uptake and localization of a Cy3-labeled siRNA specific for the serine/threonine kinase Pim-1. Oligonucleotides (2003) 13(5):345-352.
57. 3 receptor. Nucleic Acids Res (2003) 31(8):2117-2126.
58. oα: Mediation of extracellular signal-regulated kinase activation by opioid receptors in neural cells. J Neurochem (2003) 86(5):1213-1222.
59. Zhang Y, Boado RJ, Pardridge WM: In vivo knockdown of gene expression In brain cancer with intravenous RNAi in adult rats. J Gene Med (2003) 5(12):1039-1045. A strategy is developed to knockdown gene expression in the brain after intravenous injection of immunoliposome-encapsulated vectors.
60. Chi JT, Chang HY, Wang NN, Chang DS, Dunphy N, Brown PO: Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci USA (2003) 100(11):6343-6346.
61. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW: Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA (2003) 100(11):6347-6352.
62. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 21(6):635-637.
63. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet (2003) 34(3):263-264.
64. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR: Activation of the interferon system by short-interfering RNAs. Nat Cell Biol (2003) 5(9):834-839.
65. Check E: Gene regulation: RNA to the rescue? Nature (2003) 425(6953):10-12.